ArticleFrontiers in pharmacology2026
Itaconate alleviates thioacetamide-induced acute liver injury by suppressing pyroptosis-associated mitochondrial dysfunction and activating the Nrf2/HO-1 pathway.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute liver injury is closely associated with inflammatory responses, oxidative stress, hepatocyte death, and mitochondrial dysfunction, whereas effective pharmacological strategies remain limited. This study aimed to investigate the protective effect of 4-octyl itaconate (4-OI) against thioacetamide (TAA)-induced acute liver injury and to further explore the underlying mechanisms. A TAA-induced acute liver injury mouse model, an LPS-stimulated RAW264.7 macrophage inflammatory model, and an LPS/nigericin-stimulated bone marrow-derived macrophage (BMDM) pyroptosis model were established. Liver injury, inflammatory responses, oxidative stress, hepatocyte apoptosis, pyroptosis, and mitochondrial dysfunction were evaluated using histopathological staining, TUNEL staining, biochemical assays, ELISA, qPCR, Western blotting, LDH release assay, immunofluorescence staining, PI staining, MitoSOX staining, and JC-1 assay. ML385 was used to inhibit nuclear factor erythroid 2-related factor 2 (Nrf2) signaling. 4-OI markedly alleviated TAA-induced liver injury, as shown by improved liver histology, reduced hepatocyte apoptosis and macrophage infiltration, decreased serum transaminase levels, and suppressed inflammatory cytokine production. In parallel, 4-OI activated the Nrf2/heme oxygenase-1 (HO-1) pathway, whereas pharmacological inhibition of Nrf2 by ML385 partially reversed its hepatoprotective and anti-inflammatory effects. Increased hepatic GSDMD-N expression after TAA exposure was also reduced by 4-OI. In LPS/nigericin-stimulated BMDMs, 4-OI decreased NOD-like receptor family pyrin domain-containing 3 (NLRP3), cleaved caspase-1, and GSDMD-N expression, accompanied by reduced LDH release, IL-1β secretion, PI-positive cell death, and mitochondrial reactive oxygen species production, as well as restored mitochondrial membrane potential. Moreover, 4-OI reduced mitochondrial GSDMD-N accumulation and attenuated mtDNA-induced pyroptotic activation. These findings indicate that 4-OI alleviates TAA-induced acute liver injury, at least in part, through activation of the Nrf2/HO-1 signaling pathway and suppression of pyroptotic activation and mitochondrial dysfunction-associated inflammatory amplification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.